nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroergotamine—Ergoloid mesylate—DRD2—Gilles de la Tourette syndrome	0.019	0.283	CrCbGaD
Dihydroergotamine—HTR6—Serotonin receptors—HTR2A—Gilles de la Tourette syndrome	0.018	0.0231	CbGpPWpGaD
Dihydroergotamine—HTR1D—Serotonin receptors—HTR2A—Gilles de la Tourette syndrome	0.0178	0.0229	CbGpPWpGaD
Dihydroergotamine—HTR1B—Serotonin receptors—HTR2A—Gilles de la Tourette syndrome	0.0175	0.0224	CbGpPWpGaD
Dihydroergotamine—HTR2B—Serotonin receptors—HTR2A—Gilles de la Tourette syndrome	0.0164	0.0211	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0148	0.019	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0147	0.0189	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0144	0.0185	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0135	0.0174	CbGpPWpGaD
Dihydroergotamine—HTR1A—Serotonin receptors—HTR2A—Gilles de la Tourette syndrome	0.0133	0.0171	CbGpPWpGaD
Dihydroergotamine—HTR6—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0126	0.0162	CbGpPWpGaD
Dihydroergotamine—HTR1D—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0125	0.0161	CbGpPWpGaD
Dihydroergotamine—HTR1B—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0123	0.0158	CbGpPWpGaD
Dihydroergotamine—HTR6—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0123	0.0157	CbGpPWpGaD
Dihydroergotamine—HTR1D—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0122	0.0156	CbGpPWpGaD
Dihydroergotamine—Bromocriptine—DRD4—Gilles de la Tourette syndrome	0.012	0.179	CrCbGaD
Dihydroergotamine—HTR1B—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0119	0.0153	CbGpPWpGaD
Dihydroergotamine—HTR2B—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0115	0.0148	CbGpPWpGaD
Dihydroergotamine—HTR6—nervous system—Gilles de la Tourette syndrome	0.0115	0.0745	CbGeAlD
Dihydroergotamine—HTR6—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0114	0.0147	CbGpPWpGaD
Dihydroergotamine—HTR1D—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0113	0.0146	CbGpPWpGaD
Dihydroergotamine—HTR2B—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0112	0.0144	CbGpPWpGaD
Dihydroergotamine—HTR1B—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0111	0.0143	CbGpPWpGaD
Dihydroergotamine—HTR6—central nervous system—Gilles de la Tourette syndrome	0.011	0.0717	CbGeAlD
Dihydroergotamine—HTR1A—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.011	0.0141	CbGpPWpGaD
Dihydroergotamine—HTR2B—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HTR2A—Gilles de la Tourette syndrome	0.0109	0.014	CbGpPWpGaD
Dihydroergotamine—HTR6—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0106	0.0136	CbGpPWpGaD
Dihydroergotamine—HTR1D—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0105	0.0135	CbGpPWpGaD
Dihydroergotamine—HTR2B—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0104	0.0134	CbGpPWpGaD
Dihydroergotamine—HTR1B—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0103	0.0132	CbGpPWpGaD
Dihydroergotamine—Bromocriptine—DRD3—Gilles de la Tourette syndrome	0.0103	0.154	CrCbGaD
Dihydroergotamine—HTR6—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0103	0.0132	CbGpPWpGaD
Dihydroergotamine—HTR1D—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0102	0.0131	CbGpPWpGaD
Dihydroergotamine—HTR1B—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.01	0.0129	CbGpPWpGaD
Dihydroergotamine—HTR2B—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.00969	0.0124	CbGpPWpGaD
Dihydroergotamine—HTR6—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0096	0.0123	CbGpPWpGaD
Dihydroergotamine—HTR1D—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.00953	0.0122	CbGpPWpGaD
Dihydroergotamine—HTR2B—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.00941	0.0121	CbGpPWpGaD
Dihydroergotamine—HTR1A—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.00935	0.012	CbGpPWpGaD
Dihydroergotamine—HTR1B—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.00933	0.012	CbGpPWpGaD
Dihydroergotamine—HTR1A—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.00908	0.0117	CbGpPWpGaD
Dihydroergotamine—HTR6—brain—Gilles de la Tourette syndrome	0.00877	0.057	CbGeAlD
Dihydroergotamine—HTR2B—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.00877	0.0113	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.00862	0.0111	CbGpPWpGaD
Dihydroergotamine—HTR1A—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.00846	0.0109	CbGpPWpGaD
Dihydroergotamine—HTR1B—midbrain—Gilles de la Tourette syndrome	0.00841	0.0546	CbGeAlD
Dihydroergotamine—HTR1D—midbrain—Gilles de la Tourette syndrome	0.00814	0.0529	CbGeAlD
Dihydroergotamine—HTR6—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.008	0.0103	CbGpPWpGaD
Dihydroergotamine—HTR1D—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00794	0.0102	CbGpPWpGaD
Dihydroergotamine—HTR1A—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.00786	0.0101	CbGpPWpGaD
Dihydroergotamine—HTR1B—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00778	0.00998	CbGpPWpGaD
Dihydroergotamine—HTR1A—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.00763	0.0098	CbGpPWpGaD
Dihydroergotamine—Ergotamine—DRD2—Gilles de la Tourette syndrome	0.0074	0.11	CrCbGaD
Dihydroergotamine—ADRA2A—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.00735	0.00944	CbGpPWpGaD
Dihydroergotamine—HTR2B—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0073	0.00938	CbGpPWpGaD
Dihydroergotamine—Bromocriptine—DRD2—Gilles de la Tourette syndrome	0.00714	0.107	CrCbGaD
Dihydroergotamine—ADRA2A—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.00714	0.00916	CbGpPWpGaD
Dihydroergotamine—HTR1A—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.00711	0.00913	CbGpPWpGaD
Dihydroergotamine—HTR1B—nervous system—Gilles de la Tourette syndrome	0.00691	0.0449	CbGeAlD
Dihydroergotamine—HTR1A—midbrain—Gilles de la Tourette syndrome	0.00679	0.0441	CbGeAlD
Dihydroergotamine—HTR6—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00673	0.00863	CbGpPWpGaD
Dihydroergotamine—HTR1D—nervous system—Gilles de la Tourette syndrome	0.00669	0.0435	CbGeAlD
Dihydroergotamine—HTR1D—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00668	0.00857	CbGpPWpGaD
Dihydroergotamine—HTR1B—central nervous system—Gilles de la Tourette syndrome	0.00666	0.0432	CbGeAlD
Dihydroergotamine—ADRA2A—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.00665	0.00853	CbGpPWpGaD
Dihydroergotamine—HTR1B—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00654	0.00839	CbGpPWpGaD
Dihydroergotamine—HTR1D—central nervous system—Gilles de la Tourette syndrome	0.00644	0.0419	CbGeAlD
Dihydroergotamine—HTR2B—nervous system—Gilles de la Tourette syndrome	0.00623	0.0404	CbGeAlD
Dihydroergotamine—ADRA2A—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.00618	0.00793	CbGpPWpGaD
Dihydroergotamine—HTR2B—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00614	0.00788	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.006	0.0077	CbGpPWpGaD
Dihydroergotamine—HTR2B—central nervous system—Gilles de la Tourette syndrome	0.006	0.0389	CbGeAlD
Dihydroergotamine—HTR1A—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00592	0.0076	CbGpPWpGaD
Dihydroergotamine—Ergotamine—HTR2A—Gilles de la Tourette syndrome	0.00572	0.0854	CrCbGaD
Dihydroergotamine—ADRA2A—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.00559	0.00717	CbGpPWpGaD
Dihydroergotamine—HTR1A—nervous system—Gilles de la Tourette syndrome	0.00558	0.0362	CbGeAlD
Dihydroergotamine—Bromocriptine—HTR2A—Gilles de la Tourette syndrome	0.00552	0.0823	CrCbGaD
Dihydroergotamine—HTR1A—central nervous system—Gilles de la Tourette syndrome	0.00537	0.0349	CbGeAlD
Dihydroergotamine—HTR1B—brain—Gilles de la Tourette syndrome	0.00528	0.0343	CbGeAlD
Dihydroergotamine—HTR1D—brain—Gilles de la Tourette syndrome	0.00512	0.0332	CbGeAlD
Dihydroergotamine—HTR1A—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00498	0.00639	CbGpPWpGaD
Dihydroergotamine—HTR2B—brain—Gilles de la Tourette syndrome	0.00476	0.0309	CbGeAlD
Dihydroergotamine—ADRA2A—midbrain—Gilles de la Tourette syndrome	0.00476	0.0309	CbGeAlD
Dihydroergotamine—ADRA2A—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00466	0.00598	CbGpPWpGaD
Dihydroergotamine—HTR1A—brain—Gilles de la Tourette syndrome	0.00426	0.0277	CbGeAlD
Dihydroergotamine—ADRA2A—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00391	0.00502	CbGpPWpGaD
Dihydroergotamine—ADRA2A—nervous system—Gilles de la Tourette syndrome	0.00391	0.0254	CbGeAlD
Dihydroergotamine—ADRA2A—central nervous system—Gilles de la Tourette syndrome	0.00377	0.0245	CbGeAlD
Dihydroergotamine—CYP3A4—nervous system—Gilles de la Tourette syndrome	0.00308	0.02	CbGeAlD
Dihydroergotamine—ADRA2A—brain—Gilles de la Tourette syndrome	0.00299	0.0194	CbGeAlD
Dihydroergotamine—CYP3A4—central nervous system—Gilles de la Tourette syndrome	0.00296	0.0193	CbGeAlD
Dihydroergotamine—ABCB1—midbrain—Gilles de la Tourette syndrome	0.00265	0.0172	CbGeAlD
Dihydroergotamine—HTR1D—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00261	0.00335	CbGpPWpGaD
Dihydroergotamine—HTR1B—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00255	0.00328	CbGpPWpGaD
Dihydroergotamine—HTR1D—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00253	0.00325	CbGpPWpGaD
Dihydroergotamine—HTR1B—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00248	0.00318	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00244	0.00313	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00242	0.00311	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00237	0.00304	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00237	0.00304	CbGpPWpGaD
Dihydroergotamine—HTR1D—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00236	0.00303	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00235	0.00302	CbGpPWpGaD
Dihydroergotamine—HTR1B—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00231	0.00296	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.0023	0.00295	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00223	0.00286	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.0022	0.00283	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00219	0.00281	CbGpPWpGaD
Dihydroergotamine—ABCB1—nervous system—Gilles de la Tourette syndrome	0.00218	0.0142	CbGeAlD
Dihydroergotamine—HTR2B—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00216	0.00277	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00214	0.00275	CbGpPWpGaD
Dihydroergotamine—ABCB1—central nervous system—Gilles de la Tourette syndrome	0.0021	0.0136	CbGeAlD
Dihydroergotamine—HTR6—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00209	0.00268	CbGpPWpGaD
Dihydroergotamine—HTR1D—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00207	0.00266	CbGpPWpGaD
Dihydroergotamine—HTR1B—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00203	0.00261	CbGpPWpGaD
Dihydroergotamine—HTR6—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00203	0.0026	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00201	0.00258	CbGpPWpGaD
Dihydroergotamine—HTR1D—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00201	0.00258	CbGpPWpGaD
Dihydroergotamine—HTR1B—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00197	0.00253	CbGpPWpGaD
Dihydroergotamine—HTR1A—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00194	0.0025	CbGpPWpGaD
Dihydroergotamine—HTR2B—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00191	0.00245	CbGpPWpGaD
Dihydroergotamine—HTR6—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00189	0.00242	CbGpPWpGaD
Dihydroergotamine—HTR1A—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00189	0.00242	CbGpPWpGaD
Dihydroergotamine—HTR1D—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00187	0.00241	CbGpPWpGaD
Dihydroergotamine—HTR2B—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00185	0.00238	CbGpPWpGaD
Dihydroergotamine—HTR1B—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00184	0.00236	CbGpPWpGaD
Dihydroergotamine—HTR2B—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.00182	0.00234	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.0018	0.00232	CbGpPWpGaD
Dihydroergotamine—HTR1A—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00176	0.00226	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00175	0.00225	CbGpPWpGaD
Dihydroergotamine—HTR2B—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00172	0.00221	CbGpPWpGaD
Dihydroergotamine—HTR1A—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.00171	0.00219	CbGpPWpGaD
Dihydroergotamine—ABCB1—brain—Gilles de la Tourette syndrome	0.00167	0.0108	CbGeAlD
Dihydroergotamine—HTR1A—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00163	0.0021	CbGpPWpGaD
Dihydroergotamine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00163	0.00209	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00159	0.00204	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00158	0.00203	CbGpPWpGaD
Dihydroergotamine—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00155	0.00198	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00155	0.00198	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00154	0.00198	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00154	0.00198	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00153	0.00197	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00153	0.00197	CbGpPWpGaD
Dihydroergotamine—ADRA2A—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00153	0.00196	CbGpPWpGaD
Dihydroergotamine—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.0015	0.00193	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.0015	0.00193	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.0015	0.00193	CbGpPWpGaD
Dihydroergotamine—ADRA2A—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00148	0.0019	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00145	0.00186	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00144	0.00185	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00143	0.00183	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00142	0.00182	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00141	0.00181	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00141	0.00181	CbGpPWpGaD
Dihydroergotamine—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.0014	0.0018	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.0014	0.00179	CbGpPWpGaD
Dihydroergotamine—ADRA2A—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00138	0.00177	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00138	0.00177	CbGpPWpGaD
Dihydroergotamine—HTR6—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00132	0.0017	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00131	0.00169	CbGpPWpGaD
Dihydroergotamine—HTR1D—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00131	0.00169	CbGpPWpGaD
Dihydroergotamine—HTR1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00129	0.00165	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00128	0.00165	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00122	0.00156	CbGpPWpGaD
Dihydroergotamine—HTR2B—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00121	0.00155	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00118	0.00151	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00118	0.00151	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00114	0.00147	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00114	0.00147	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.0011	0.00141	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00106	0.00137	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00101	0.00129	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.001	0.00128	CbGpPWpGaD
Dihydroergotamine—HTR1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000979	0.00126	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000979	0.00126	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000925	0.00119	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00092	0.00118	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000899	0.00115	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000898	0.00115	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000898	0.00115	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000892	0.00115	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—HDC—Gilles de la Tourette syndrome	0.000887	0.00114	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000873	0.00112	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000873	0.00112	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000866	0.00111	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000848	0.00109	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000837	0.00107	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000821	0.00105	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000816	0.00105	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000813	0.00104	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00081	0.00104	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000807	0.00104	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000797	0.00102	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000793	0.00102	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000792	0.00102	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00079	0.00101	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000786	0.00101	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00077	0.000988	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00077	0.000988	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000746	0.000957	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000745	0.000956	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000742	0.000953	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000738	0.000948	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000733	0.00094	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000723	0.000929	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000717	0.000921	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000674	0.000865	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000665	0.000854	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000646	0.000829	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—HDC—Gilles de la Tourette syndrome	0.000614	0.000788	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000604	0.000776	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000602	0.000772	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000587	0.000753	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000586	0.000752	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000569	0.000731	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000565	0.000725	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000553	0.00071	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000546	0.000701	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000523	0.000671	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.00052	0.000667	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000517	0.000664	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000513	0.000659	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000508	0.000652	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000502	0.000645	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000482	0.000619	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000479	0.000614	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000475	0.00061	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000473	0.000607	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000472	0.000606	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000469	0.000601	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000468	0.000601	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000465	0.000596	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000461	0.000592	CbGpPWpGaD
Dihydroergotamine—ABCB1—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.000456	0.000585	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000455	0.000584	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00044	0.000565	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000436	0.00056	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000433	0.000556	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00043	0.000551	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000427	0.000549	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000424	0.000544	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000421	0.000541	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000398	0.000511	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000383	0.000491	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—HDC—Gilles de la Tourette syndrome	0.000378	0.000485	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000357	0.000458	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000347	0.000445	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000331	0.000425	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000323	0.000414	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000305	0.000392	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000303	0.000389	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000301	0.000386	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000297	0.000381	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000281	0.00036	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000279	0.000358	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000272	0.00035	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000254	0.000326	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000226	0.00029	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000178	0.000228	CbGpPWpGaD
